Navigation Links
Antigen Discovery Inc. Awarded Phase I SBIR Grant to Develop a Fully Integrated Microfluidic Point of Care Diagnostic Device
Date:8/15/2012

IRVINE, Calif., Aug. 15, 2012 /PRNewswire/ -- Antigen Discovery Inc. (ADi) today announced that it has received a Phase I Small Business Innovation and Research (SBIR) award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The two-year $600,000 award will fund a collaborative research effort between ADi and the Henry Samueli School of Engineering at University of California, Irvine (UCI) to develop a fully integrated microfluidic immunodiagnostic platform.  Threats from infectious disease have been growing at an alarming pace worldwide; there is a critical need for accurate, rapid, and readily deployable diagnostics during mass disasters, natural disease outbreaks, and bioterrorist threats.  This joint effort will take advantage of a novel air-liquid cavity acoustic transducer (ALCAT) technology pioneered by Dr. Abraham Lee's group at UCI, and ADi's protein microarray technology and large library of serodiagnostic antigens from dozens of infectious disease targets.  Dr. Xiaowu Liang, President and CEO of ADi, states that "the development of hand-held point-of-care (POC) diagnostics will meet a vital need as the portability, ease-of-use, and prompt sample-to-answer times allow first responders to effectively assess the prevalence and spread of exposure in a population during major outbreaks."  

"We will design and build a microfluidic polymer-based chip that utilizes ALCAT which provides the fluid actuation required for complex reagent handling in multi-step colorimetric immunoassays," added Dr. Abraham Lee, Principle Investigator, Chair of the Department of Biomedical Engineering and Director of the Micro/nano Fluidics Fundamentals Focus (MF3) Center at UCI. "ALCAT's versatility as a single actuation technology is an easier method for on-chip integration compared to other POC platforms that require a different actuator for each fluidic process. By incorporating novel ALCAT-based approaches into protein microarray assays, we will have the versatility and power to reduce enzymatic development times, limit production costs, and fully integrate all components into a disposable assay."

While ADi has received a number of SBIR/STTR awards in the past, this is the first time the company has received a grant for development of a medical device. "Thanks to support from the NIAID, we have been able to build a significant portfolio of diagnostic markers for a wide range of infectious agents," said Dr. Philip Felgner, Founder and Chairman of ADi. "We now plan to develop a point-of-care diagnostic system consisting of a cost-effective disposable microfluidic plastic chip and a portable analyzer that can be driven by a mobile computing device such as a smart phone for rapid serological evaluation of exposure and infections."

About Antigen Discovery Inc.
Antigen Discovery Inc. is a privately owned biotechnology company located in Irvine, California. ADi has a proprietary high throughput proteomics platform technology for biomarker discovery. The company uses and commercializes its innovative proteome microarrays and testing models to facilitate the development of new diagnostic tests, therapeutics and vaccines for infectious disease, autoimmunity, cancer and more. For more information about ADi, see http://www.antigendiscovery.com.

Contact:

Angela Yee
ayee@antigendiscovery.com


'/>"/>
SOURCE Antigen Discovery Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
2. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
3. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
4. Generex Augments Antigen Express Scientific Advisory Board
5. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
6. Antigen Discovery, Inc. Awarded Phase II SBIR Grant to Identify Biomarkers Associated with Protection against Malaria
7. TeraDiscoveries to Use its Inverse Design Software Running on Windows Azure to Advance Its Computational Drug Discovery Process
8. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
9. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
10. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
11. Dr. Paul Karila Appointed Head of Discovery Services at Cellectricon AB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/22/2017)... Sept. 22, 2017 AVACEN Medical (AVACEN) announced ... now successfully helping those with the widespread pain associated ... diagnosed Amanda in Essex, England ... my hair, experiencing no sleep at all, tremendous pain, ... I cannot recommend [the AVACEN 100] enough, how this ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed ... geared towards children of all ages; it is a non-competitive, non-timed event, which is ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
Breaking Medicine News(10 mins):